Drug Profile
Captisol-enabled busulfan - Ligand Pharmaceuticals
Alternative Names: CE-BusulfanLatest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Developer Ligand Pharmaceuticals; University of Kansas
- Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
- Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Haematological malignancies
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 29 Aug 2023 Preclinical development is ongoing in USA (unspecified route)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
- 01 Sep 2015 Captisol-enabled busulfan is available for licensing as of 01 Sep 2015. http://www.ligand.com/